News

News 29.06.2022 Zurich-Schlieren, Switzerland, June 29, 2022. Proteomedix, a Swiss diagnostics company committed to advance prostate cancer care, today announced that new data will be presented showing that Proclarix® can be used with high confidence by reliably identifying clinically significant prostate cancer and safely ruling out negative cases. Study results will be presented...

News 07.06.2022 Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – June 7, 2022 – ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced the closing of an oversubscribed Series B financing round totaling $74 million....

News 02.06.2022 Schlieren (Zurich), Switzerland, June 2, 2022 – Kuros Biosciences AG (“Kuros” or the “Company”), a leader in next generation bone graft technologies, notes the completion of the acquisition of Checkmate Pharmaceuticals (NASDAQ: CMPI) by Regeneron Pharmaceuticals (NASDAQ: REGN). The completion triggers a $5 million milestone payment under a license agreement...

Events, External events
Event date: 27.10.2022 insel-sitem, Bern An integrative program, equipped with distinguished speakers will have you dive into translational medicine in a unique community atmosphere. Dive in and learn from the experts, get further insights into the operational excellence of translational research and help shape translational medicine in the future! This day provides you...

News 31.05.2022 Schlieren (Zurich), Switzerland, May 31, 2022 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today promising preliminary results from the first of its five planned randomized controlled trials for its MagnetOs family, comparing MagnetOs Granules to the gold standard of autograft bone. Data from...